Circulation - "Mesenchymal Precursor Cells as Adjunctive Therapy in Recipients of Contemporary LVADs"

Allogeneic mesenchymal precursor cells (MPC) injected during left ventricular assist device (LVAD) implantation may contribute to myocardial recovery. This trial explores the safety and efficacy of this strategy.

New York, NY
 – March 28, 2014  –– 

In this multi-center, double-blind, sham-procedure controlled trial, 30 patients were randomized to intramyocardial injection of 25M MPCs or medium during LVAD implantation. The primary safety endpoint was incidence of infectious myocarditis, myocardial rupture, neoplasm, hypersensitivity reaction, and immune sensitization (90 days post-randomization). Key efficacy endpoints were functional status and ventricular function, while temporarily weaned from LVAD support (90 days post-randomization). Learn more